Balancing quality-of-life concerns with treatment goals is complicated for young patients with hormone-sensitive breast cancers.
In the current digital age, where all-too-personal information flows from Facebook and Twitter, it seems that the health information available through the process of genetic testing would be an idea welcomed by most of the public.
For patients with cancer, their journey does not end after treatment is over.
Deirdre Kiely, MS, MPA, RN, ANP, nurse practitioner, Perlmutter Cancer Center at NYU Langone Medical Center, discusses some of the challenges of getting breast cancer patients to exercise routinely.
When patients with MCL develop resistance to chemotherapy and targeted therapies, experts believe CAR T-cell therapy can step in.
Debu Tripathy discuss how to encouragecompliance and adherence for patients with breast cancer who are receiving hormone therapy.
Carol Tringali on Closing the Gaps in Psychosocial Care
There are some adverse events that are common to all PARP inhibitors, and others that are specific to each drug.
Melanie A. Nix, co-founder of the Breast Cancer Comfort Site, comments on the importance of social media in advocacy.
Mary McCabe, director, Cancer Survivorship Initiative, Memorial Sloan Kettering Cancer Center, discusses the evolution of survivorship care.
About a third of breast cancer survivors are still living with fatigue and reduced exercise capacity after treatment ends.
Survivors of childhood cancer who are overweight or obese as adults are at an increased risk of developing an obesity-related cancer.
Robert Andtbacka, MD, associate professor, Division of Surgical Oncology Department of Surgery, University of Utah School of Medicine, discusses past, present, and future trials for T-VEC.
Mark E. Robson, MD, Clinical Director of the Clinical Genetics Services at Memorial Sloan Kettering Cancer Center, discusses when it is appropriate to go for genetic testing to determine cancer risk.
Kathleen M. Madden discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.
Gregory T. Armstrong, MD, MSCE, pediatric oncologist, St. Jude Children's Research Hospital, discusses a trial of 34,000 childhood cancer survivors.
Research has shown that pain and anxiety are related to port access, so a need exists to capture patients’ feelings and emotions related to living with a port, as well as effective nursing interventions aimed at addressing those patient experiences.
Colleen Jennings, RN, BSN, HN-BC, discusses how to improve follow-up phone calls.
Sacituzumab govitecan may represent a promising option for patients with endocrine resistant, hormone receptor–positive/HER2-negative metastatic breast cancer, according to updated findings from the phase 3 TROPiCs-02 study.
John Kirkwood, MD, Usher professor, Medicine, Dermatology and Translational Science, co-director, Melanoma and Skin Cancer Program, University of Pittsburgh, discusses training physicians on skin examinations for detecting melanoma.Â
Using integrative modalities such as behavior therapies, mindfulness meditation and creative arts therapy can support a patient with cancer during treatment.
Up to 40% of patients with cancer who take opioids experience nausea and vomiting.
Please enjoy this music while your party is reached … "Hello, Mr. Freeman,* this is Venteria Knight. I'm a nurse navigator with Northside Hospital, and we met at the prostate cancer screening last week."
Daniela Delbeau, RN, clinical research nurse coordinator at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses how individuals react differently to treatment.
As I looked at Ms C, I was struck by the pensive but engaged smile she always sent my way. The same look continued as her daughter elaborated on her mother's condition.
Jean Sellers, RN, MSN, administrative clinical director, UNC Lineberger Comprehensive Cancer Center, discusses how to be a successful oncology nurse navigator.
Cancer centers throughout the country are faced with an increased demand for cancer care and a shrinking oncology workforce.1 As a result, institutions are struggling to find innovative ways to deliver patient-centered quality care in a cost-effective manner.